Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
OTC Drugs

GSK Divests Non-Core OTCs To Focus On "Priority Brands," Emerging Markets

This article was originally published in The Tan Sheet

  • News

Executive Summary

GlaxoSmithKline will divest non-core OTC products to accelerate consumer health care growth and help fund a share buy-back program following a financial wipeout in the firm's most recent quarter.

You may also be interested in...



Central, Eastern Europe Lead OTC Growth On Sector's Top Continent

Central and Eastern Europe continue to drive OTC sales growth on the continent, with even low-growth countries matching the best levels in Western Europe

Central, Eastern Europe Lead OTC Growth On Sector’s Top Continent

Central and Eastern Europe continue to drive OTC sales growth on the continent, with even low-growth countries matching the best levels in Western Europe.

Central, Eastern Europe Lead OTC Growth On Sector’s Top Continent

Central and Eastern Europe continue to drive OTC sales growth on the continent, with even low-growth countries matching the best levels in Western Europe.

Table

View full table

Related Content

Pink Sheet
HBW Insight
Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
OTC Drugs
UsernamePublicRestriction

Register

OM002075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By